Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer
Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer
复制标题
DOI：
10.1016/j.mce.2017.02.004
复制
发表时间：
2017-11-15
影响因子：
4.1
通讯作者：
Klinge, Carolyn M.
中科院分区：
文献类型：
--
作者：
Muluhngwi, Penn;Klinge, Carolyn M.
针对雌激素受体α(ERα)的治疗方法，包括选择性雌激素受体调节剂(SERM)他莫昔芬和芳香酶抑制剂(AI)，如来曲唑，已被证明在降低最初肿瘤表达ERα的乳腺癌患者的死亡率方面取得了成功。然而，大约40%的患者对这些内分泌治疗产生获得性抵抗力。迫切需要开发灵敏的循环生物标记物，准确识别内分泌治疗耐药的乳腺癌患者改变的信号通路。血清miRNAs具有肿瘤特异性表达和稳定性，有可能作为内分泌抵抗型乳腺癌进展的生物标志物。MiRNAs的胞外转移与肿瘤转移和内分泌耐药有关。这篇综述集中在乳腺癌患者的乳腺肿瘤和分泌物中的miRNAs，这些miRNAs与他莫昔芬的耐药性有关，因为它是最好的研究对象。(C)2017爱思唯尔B.V.保留所有权利。
Therapies targeting estrogen receptor alpha (ER alpha) including tamoxifen, a selective estrogen receptor modulator (SERM) and aromatase inhibitors (AI), e.g., letrozole, have proven successful in reducing the death rate for breast cancer patients whose initial tumors express ER alpha. However, about 40% of patients develop acquired resistance to these endocrine treatments. There is a critical need to develop sensitive circulating biomarkers that accurately identify signaling pathways altered in breast cancer patients resistant to endocrine therapies. Serum miRNAs have the potential to serve as biomarkers of the progression of endocrine-resistant breast cancer due to their cancer-specific expression and stability. Exosomal transfer of miRNAs has been implicated in metastasis and endocrine-resistance. This review focuses on miRNAs in breast tumors and in scrum, including exosumes, from breast cancer patients that are associated with resistance to tamoxifen since it is best-studied. (C) 2017 Elsevier B.V. All rights reserved.